이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

이것은 다발성 경화증(MS) 참가자에서 Ocrelizumab의 안전성과 유효성을 조사하기 위한 Roche P-시험의 확장 연구입니다.

2026년 8월 28일 업데이트: Hoffmann-La Roche

이전에 A F. Hoffmann-La Roche가 후원하는 Ocrelizumab IIIb/IV 임상 시험에 등록된 다발성 경화증 환자에서 Ocrelizumab의 효과 및 안전성을 평가하기 위한 단일군, 개방형 라벨 다기관 확장 연구

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

연구 개요

상태

완전한

개입 / 치료

상세 설명

This is a single arm, open label, multicenter extension study in participants who completed treatment period with ocrelizumab in the Roche P-trials. Participants will receive treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.

연구 유형

중재적

등록 (실제)

1055

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • 's-Hertogenbosch, 네덜란드, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Amsterdam, 네덜란드, 1081 HV
        • Amsterdam UMC Location VUMC
      • Breda, 네덜란드, 4819 EV
        • Amphia Ziekenhuis
      • Gouda, 네덜란드, 2803 HH
        • Groene Hart Ziekenhuis
      • NL -rotterdam, 네덜란드, 3079 DZ
        • Maasstadziekenhuis
      • Sittard-Geleen, 네덜란드, 6162 BG
        • Zuyderland Medisch Centrum - Sittard Geleen
      • Tilburg, 네덜란드, 5022 GC
        • Elisabeth-TweeSteden Ziekenhuis
      • Bergen, 노르웨이, 5021
        • Haukeland universitetssykehus
      • Drammen, 노르웨이, 3004
        • Sykehuset Buskerud HF
      • Stavanger, 노르웨이, 4011
        • Stavanger Universitetssykehus, Helse Stavanger HF
      • Aalborg, 덴마크, 9000
        • Aalborg Universitetshospital
      • Aarhus N, 덴마크, 8200
        • Aarhus Universitetshospital
      • Glostrup Municipality, 덴마크, 2600
        • Rigshospitalet Glostrup
      • Odense C, 덴마크, 5000
        • Odense Universitetshospital, Neurologisk Afdeling N
      • Sønderborg, 덴마크, 6400
        • Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
      • Mexico City, 멕시코, 14050
        • Unidad de investigacion en salud (UIS)
    • Mexico CITY (federal District)
      • Mexico City, Mexico CITY (federal District), 멕시코, 06726
        • Hospital General de México
    • Sinaloa
      • Culiacán, Sinaloa, 멕시코, 80020
        • Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
      • Bruges, 벨기에, 8000
        • AZ Sint Jan
      • Edegem, 벨기에, 2650
        • UZ Antwerpen
      • La Louvière, 벨기에, 7100
        • CHU Tivoli
      • Liège, 벨기에, 4000
        • CHU de Liège (Sart Tilman)
      • Overpelt, 벨기에, 3900
        • Revalidatie en MS Centrum
      • Sofia, 불가리아, 1113
        • Shat Np Sveti Naum
      • Sofia, 불가리아, 1309
        • Multiprofile Hosp. for Active Treatment
    • Paraná
      • Curitiba, Paraná, 브라질, 81210-310
        • Instituto de Neurologia de Curitiba
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, 브라질, 90610-000
        • Hospital Sao Lucas - PUCRS
    • São Paulo
      • São Paulo, São Paulo, 브라질, 05403-900
        • Hospital das Clinicas - FMUSP
      • Gothenburg, 스웨덴, 413 45
        • Sahlgrenska Sjukhuset
      • Karlstad, 스웨덴, 65185
        • Centralsjukhuset
      • Stockholm, 스웨덴, 113 41
        • Centrum för Neurologi
      • Barcelona, 스페인, 08035
        • Hospital Vall d'Hebron
      • Cadiz, 스페인, 11009
        • Hospital Puerta del Mar
      • Girona, 스페인, 17007
        • Hospital Universitari de Girona Dr. Josep Trueta
      • Madrid, 스페인, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, 스페인, 28046
        • Hospital Universitario La Paz
      • Madrid, 스페인, 28006
        • Universitario de La Princesa
      • Madrid, 스페인, 28040
        • Hospital Universitario Clínico San Carlos
      • Murcia, 스페인
        • Hospital Universitario Virgen de Arrixaca
      • Seville, 스페인, 41009
        • Hospital Universitario Virgen Macarena
      • Valencia, 스페인, 46010
        • Hospital Clinico Universitario de Valencia
      • Valencia, 스페인, 46026
        • Hospital Universitario la Fe
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08907
        • Hospital Universitari de Bellvitge
    • Castellon
      • Castellon, Castellon, 스페인, 12004
        • Hospital General de Castellon
    • LA Coruna
      • A Coruña, LA Coruna, 스페인, 15006
        • Complejo Hospitalario Universitario A Coruña (CHUAC)
    • Lerida
      • Lleida, Lerida, 스페인, 25198
        • Hospital Universitari Arnau de Vilanova de Lleida
    • Madrid
      • Pozuelo de Alarcón, Madrid, 스페인, 28223
        • Hospital Quiron de Madrid
    • Pontevedra
      • Vigo, Pontevedra, 스페인, 36312
        • Complejo Hospitalario Universitario de Vigo - Xeral Cies
    • Principality of Asturias
      • Oviedo, Principality of Asturias, 스페인
        • Hospital Universitario Central de Asturias
      • Bratislava, 슬로바키아, 813 69
        • Univerzitna nemocnica Bratislava
      • Bratislava, 슬로바키아, 826 06
        • Univerzitna nemocnica Bratislava Nemocnica Ruzinov
      • Trnava, 슬로바키아, 917 75
        • Fakultna nemocnica Trnava
      • Ljubljana, 슬로베니아, 1000
        • University Medical Centre
      • Maribor, 슬로베니아, 2000
        • University Medical Centre Maribor
      • Buenos Aires, 아르헨티나, C1437JCP
        • Hospital Churruca Visca
      • Ciudad Autonoma Buenos Aires, 아르헨티나, C1061ABD
        • Centro de Especialidades Neurológicas y Rehabilitación - CENyR
      • Rosario, 아르헨티나, 2000
        • Fundacion Rosarina de Neurorehabilitacion
      • Dublin, 아일랜드
        • St Vincents University Hospital
      • Tallinn, 에스토니아, 10138
        • East Tallinn Central Hospital
      • Tallinn, 에스토니아, 10617
        • West Tallinn Central Hospital
      • Tartu, 에스토니아, 51014
        • Tartu University Hospital
      • Exeter, 영국, EX2 5DW
        • Royal Devon and Exeter Hospital (Wonford)
      • Glasgow, 영국, G51 4TF
        • Queen Elizabeth University Hospital
      • Inverness, 영국, IV2 3UV
        • Raigmore Hospital
      • Leeds, 영국, LS9 7AU
        • Leeds Teaching Hospitals NHS Trust
      • London, 영국, SW17 0QT
        • St George's Hospital
      • London, 영국, W6 8RF
        • Charing Cross Hospital
      • London, 영국, SE5 9RS
        • Kings College Hospital
      • London, 영국, E1 1BB
        • The Royal London Hospital
      • London, 영국, NW3 2QS
        • Royal Free Hospital
      • London, 영국, WC1 3BG
        • National Hospital for Neurology and Neurosurgery,
      • Newcastle upon Tyne, 영국, NE1 4LP
        • Royal Victoria Infirmary
      • Salford, 영국, M6 8HD
        • Salford Royal NHS Foundation Trust
      • Sheffield, 영국, S10 2JF
        • Royal Hallamshire Hospita
      • Swansea, 영국, SA6 6NL
        • Morriston Hospital
      • Truro, 영국, TR1 3LQ
        • Royal Cornwall Hospital
    • Abruzzo
      • Chieti, Abruzzo, 이탈리아, 66013
        • Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
      • L’Aquila, Abruzzo, 이탈리아, 67100
        • Ospedale San Salvatore
    • Apulia
      • San Giovanni Rotondo, Apulia, 이탈리아, 71013
        • IRCCS Ospedale Casa Sollievo Della Sofferenza
    • Campania
      • Naples, Campania, 이탈리아, 80131
        • A. O. U. Federico II
      • Naples, Campania, 이탈리아, 80131
        • Università degli Studi della Campania Luigi Vanvitelli
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, 이탈리아, 40139
        • Ospedale Bellaria
    • Lazio
      • Rome, Lazio, 이탈리아, 00168
        • Policlinico Universitario A. Gemelli
      • Rome, Lazio, 이탈리아, 00189
        • Azienda Ospedaliera Sant'Andrea
      • Rome, Lazio, 이탈리아, 00152
        • Ospedale S.Camillo Forlanini
      • Rome, Lazio, 이탈리아, 00133
        • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    • Liguria
      • Genoa, Liguria, 이탈리아, 16132
        • Irccs A.O.U.San Martino Ist
    • Lombardy
      • Bergamo, Lombardy, 이탈리아, 24127
        • ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
      • Gallarate, Lombardy, 이탈리아, 21013
        • Ospedale S.Antonio Abate
      • Milan, Lombardy, 이탈리아, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Lombardy, 이탈리아, 20133
        • Fond. Istituto Neurologico C.Besta
      • Milan, Lombardy, 이탈리아, 20122
        • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
      • Montichiari, Lombardy, 이탈리아, 25018
        • Ospedale Civile di Montichiari
      • Pavia, Lombardy, 이탈리아, 27100
        • IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
    • Molise
      • Pozzilli, Molise, 이탈리아, 86077
        • IRCCS Istituto Neurologico Neuromed
    • Sardinia
      • Cagliari, Sardinia, 이탈리아, 09126
        • Ospedale Binaghi
    • Sicily
      • Catania, Sicily, 이탈리아, 95123
        • AOU Policlinico V. Emanuele - P.O G. Rodolico
      • Cefalù, Sicily, 이탈리아, 90015
        • Fondazione Istituto S. Raffaele - Giglio
      • Palermo, Sicily, 이탈리아, 90129
        • AOU Policlinico Giaccone
      • Palermo, Sicily, 이탈리아, 90146
        • AO Ospedali Riuniti Villa Sofia-Cervello
    • The Marches
      • Ancona, The Marches, 이탈리아, 60100
        • AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi
    • Tuscany
      • Florence, Tuscany, 이탈리아, 50134
        • AOUC Azienda Ospedaliero-Universitaria Careggi
      • Florence, Tuscany, 이탈리아, 50134
        • AOU Careggi
      • Siena, Tuscany, 이탈리아, 53100
        • AOU Senese - Presidio Ospedaliero Le Scotte
    • Umbria
      • Perugia, Umbria, 이탈리아, 06156
        • AO di Perugia - Ospedale S. Maria della Misericordia
    • Veneto
      • Padova, Veneto, 이탈리아, 35128
        • Azienda Ospedaliera di Padova
      • Verona, Veneto, 이탈리아, 37134
        • Policlinico G.B. Rossi
      • Brno, 체코, 656 91
        • Fakultni nemocnice u sv. Anny
      • Jihlava, 체코, 58633
        • Nemocnice Jihlava
      • Prague, 체코, 12808
        • VFN Praha Poliklinika Rs Centrum - Budova A
      • Prague, 체코, 150 06
        • Fakultni nemocnice v Motole
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6T 1Z4
        • University of British Columbia
    • Ontario
      • London, Ontario, 캐나다, N6A 5A5
        • London Health Sciences Centre Uni Campus
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • The Ottawa Hospital - General Campus
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Gatineau, Quebec, 캐나다, J8Y 1W2
        • Clinique NeuroOutaouais
      • Greenfield Park, Quebec, 캐나다, J4V 2J2
        • Recherche Sepmus Inc.
      • Montreal, Quebec, 캐나다, H3A 2B4
        • Montreal Neurological Institute and Hospital
      • Kuwait City, 쿠웨이트, 10002
        • Ibn Sina Hospital
      • Zagreb, 크로아티아, 10000
        • Clinical Hospital Centre Zagreb
      • Ankara, 터키 (Türkiye), 06500
        • Gazi University Medical Faculty
      • Ankara, 터키 (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Hatay, 터키 (Türkiye), 31001
        • Mustafa Kemal Ataturk UTF
      • Istanbul, 터키 (Türkiye), 34098
        • Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
      • Istanbul, 터키 (Türkiye), 34093
        • Istanbul University Istanbul School of Medicine
      • Konya, 터키 (Türkiye), 42131
        • Selcuk University Medical Faculty
      • Samsun, 터키 (Türkiye), 55139
        • Ondokuz Mayis University School of Medicine
      • Trabzon, 터키 (Türkiye), 61080
        • Karadeniz Tecnical Uni. Med. Fac.
      • Braga, 포르투갈, 4710-243
        • Hospital de Braga
      • Coimbra, 포르투갈, 3000-075
        • HUC
      • Loures, 포르투갈, 2674-514
        • Hospital Beatriz Angelo
      • Porto, 포르투갈, 4099-001
        • Hospital Geral de Santo Antonio
      • Bydgoszcz, 폴란드, 85-796
        • Neurocentrum Bydgoszcz sp. z o.o
      • Gdansk, 폴란드, 80-803
        • COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika
      • Katowice, 폴란드, 40-568
        • Care Clinic
      • Krakow, 폴란드, 31-637
        • Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.
      • Lodz, 폴란드, 90-324
        • Centrum Neurologii Krzysztof Selmaj
      • Lublin, 폴란드, 20-410
        • Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.
      • Warsaw, 폴란드, 02-097
        • Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
      • Warsaw, 폴란드, 02-957
        • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
      • Besançon, 프랑스, 25030
        • CHU de Besancon Hopital Jean Minjoz
      • Bordeaux, 프랑스, 33076
        • Groupe Hospitalier Pellegrin
      • Bron, 프랑스, 69677
        • Hopital neurologique Pierre Wertheimer - CHU Lyon
      • Clermont-Ferrand, 프랑스, 63003
        • Hopital Gabriel Montpied CHU de Clermont-Ferrand
      • Gonesse, 프랑스, 95503
        • CH de Gonesse
      • La Tronche, 프랑스, 38700
        • CHU de Grenoble
      • Lille, 프랑스, 59037
        • Hopital Roger Salengro Service de Neurologie
      • Marseille, 프랑스, 13005
        • CHU de la Timone - Hopital d Adultes
      • Montpellier, 프랑스, 34295
        • Hopital Gui de Chauliac
      • Nancy, 프랑스, 54035
        • Hopital Central - CHU de Nancy
      • Nantes, 프랑스, 44805
        • Hôpital Guillaume et René Laënnec
      • Nice, 프랑스, 06002
        • Hôpital Pasteur
      • Nîmes, 프랑스, 30900
        • CHU de Nîmes Hopital Caremeau
      • Paris, 프랑스, 75651
        • Groupe Hospitalier Pitié- Salpétrière
      • Poissy, 프랑스, 78300
        • Hôpital de Poissy
      • Rouen, 프랑스, 76031
        • CHU de Rouen Hopital
      • Strasbourg, 프랑스, 67098
        • Höpital Hautepierre
      • Toulon, 프랑스, 83041
        • HIA de Toulon hôpital militaire
      • Turku, 핀란드, 20520
        • Mehiläinen Neo Turku
      • Budapest, 헝가리, 1204
        • Budapesti Jahn Ferenc Dél-pesti Kórház és Rendel?intézet
      • Esztergom, 헝가리, 2500
        • VALEOMED Diagnosztikai Központ

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Signed Informed Consent Form
  • Able to comply with the study protocol, in the investigator's judgment
  • Completed the treatment period of Roche sponsored ocrelizumab P-trials

Exclusion Criteria:

  • Hypersensitivity to ocrelizumab or to any of its excipients.
  • Participantss in a severely immunocompromised state until the condition resolves.
  • Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation.
  • Existence of a contra-indication as per SmPC
  • Prohibited concomitant medication as specified in protocol
  • Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Ocrelizumab

Participants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.

Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline Expanded Disability Status Scale (EDSS) score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using Kaplan-Meier(K-M) method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to Onset of CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. Disability progression was considered confirmed when increase in EDSS was confirmed at a regularly scheduled visit at least 24 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDP Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disability progression was defined as an increase of ≥ 1.0 point from the baseline EDSS score that was not attributable to another etiology (e.g., fever, concurrent illness, or concomitant medication) when the baseline score was 5.5 or less, & ≥ 0.5 when the baseline score was above 5.5. For participants with an EDSS of 0, progression is defined as a change ≥1.5 points. isability progression was considered confirmed when increase in EDSS was confirmed at two scheduled visit at least 48 weeks after initial documentation of neurological worsening. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Confirmed Disability Improvement (CDI) Sustained for at Least 24 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at a regular scheduled visit at least 24 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated &scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From CASTING Baseline to LIBERTO Week 96
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants Who Had CDI Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

CDI was defined as an improvement of ≥1 point on the EDSS score confirmed at two scheduled visits at least 48 weeks after the initial documentation of neurological status when the baseline score is 5.5 or less, and ≥ 0.5 when the baseline score is above 5.5. The CDI was measured only participants with a baseline EDSS of ≥2.0. The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as FSS. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Percentages are rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants Who Had Improved, Stable or Worsened Disability Compared With CASTING Baseline in EDSS Category at LIBERTO Week 96
기간: At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5, worsened when the change was > 0.5, and improved when the change in score was < -0.5. Percentages are rounded off.

At LIBERTO Week 96
Percentage of Participants Who Had Stable or Worsened Disability Compared With ENSEMBLE Baseline in EDSS Category at LIBERTO Week 96
기간: At LIBERTO Week 96

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Participants were considered stable when the change from baseline in score was between -0.5 and +0.5 and worsened when the change was > 0.5. Percentages are rounded off.

At LIBERTO Week 96
Change From CASTING Baseline in EDSS Score to LIBERTO Week 96
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on mixed-effect model of repeated measures (MMRM).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in EDSS Score to LIBERTO Week 96
기간: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The EDSS is based on a standard neurological examination, incorporating 7 functional systems (pyramidal, cerebellar, brainstem, sensory, bowel & bladder, visual, & cerebral) rated &scored as FSSs. Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. These ratings were then used in conjunction with observations & information concerning ambulation & use of assistive devices to determine the EDSS score. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death). Estimates are from analysis based on MMRM.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25-foot Walk Test (T25FWT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9 Hole Peg Test (9HPT) Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Median was analysed using K-M method.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 24-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in T25FWT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained T25FWT was defined as a 48-week T25FWT still has a confirmed 20% increase until the last available visit. T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant was directed to start at one end of a clearly marked 25-foot course and was instructed to walk 25 feet as quickly and safely as possible. The Examining Investigator timed the participants from the start of the walk to the end of the 25 feet. The task was immediately administered again by having the participant walk back the same distance. Participants could use assistive devices (e.g., cane, crutch, or rollator) when performing the task. Score was the average of the two completed trials, measured in seconds. The longer it takes to walk, higher the score, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 24 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 24-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With ≥ 20% Increase in 9HPT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Sustained 9HPT was defined as a 48-week 9HPT still has a confirmed 20% increase until the last available visit. In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. The longer it took complete test, higher the scores, indicating deterioration. Percentage is rounded off.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

2차 결과 측정

결과 측정
측정값 설명
기간
Time to First Protocol-Defined Event of Disease Activity
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Disease activity was defined as at least one the following events: protocol defined relapse (occurrence of new or worsening neurological symptoms attributable to MS. Symptoms must persist for > 24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications), and immediately be preceded by neurological stability for at least 30 days.); 24 weeks CDP based on increases in EDSS; a new T1 Gadolinium (Gd)-enhanced lesion; or a new and/or enlarging T2 hyperintense lesion on magnetic resonance imaging (MRI). The EDSS is based on a standard neurological examination, incorporating 7 functional systems that were rated & scored as Functional Systems Score (FSSs). Each FSS was ordinal clinical rating scale ranging from 0 to 5 or 6. EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Median was analysed using K-M method.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Time to First Relapse
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS is a disability scale that ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Annualized Protocol-Defined Relapse Rate
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

ARR=total number of relapses for all participants divided by the total years of drug exposure (from first day of infusion in parent study until LIBERTO week 96). Protocol-defined MS relapse=occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours & not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on 1 of the FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual or ≥1 point on 2 or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. EDSS scale ranges in 0.5-point steps from 0 (normal) to 10 (death). Adjusted ARR is reported.

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Relapse Free Participants
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

A protocol-defined MS relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: Symptoms persist for >24 hours and not attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications); Symptoms preceded by neurological stability for at least 30 days; Symptoms accompanied by new objective neurological worsening determined with a timely EDSS/ FSS, consistent with an increase of at least: ≥0.5 points on EDSS scale or ≥2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. or ≥1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years); From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Protocol-Defined Event of Disease Activity (NEDA) for CASTING Rollover Cohort
기간: From CASTING Baseline to LIBERTO Week 96 (up to 4 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Percentage of Participants With NEDA for ENSEMBLE Cohort
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEDA where disease activity = at least 1 of the following events: protocol defined relapse (PDR); 24 weeks CDP based on increases in EDSS while on treatment with ocrelizumab; a T1 Gd-enhanced lesion on MRI; or a new and/or enlarging T2 hyperintense lesion on MRI. PRD as defined in outcome measure 22. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS was 5.5 or less, and ≥ 0.5 when BS was above 5.5. Participants with EDSS of 0, progression was defined aschange of ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death).

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression (NEP) From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEP =no progression sustained for at least 24 weeks on: CDP; 20% increase in timed T25FWT; 20% increase in timed 9HPT yearly & over the course of the study. CDP= increase of ≥ 1.0 point from the baseline EDSS score when BS= 5.5 or less, & ≥ 0.5 when the BS= above 5.5. For participants with an EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. The EDSS disability scale ranges in 0.5-point steps from 0 (normal) to 10 (death). In T25FWT test participants walked to a 25 foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Percentage of Participants With No Evidence of Progression Sustained for at Least 24 Weeks and Disease Activity (NEPAD) From ENSEMBLE Baseline ENSEMBLE to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

Percentage of participants with NEPAD=no progression on all of the three components of NEP (CDP, T25FWT, 9HPT), no new relapse & no enlarging or new T2/ T1 Gd-enhancing lesion yearly & over the course of treatment. CDP= increase of ≥ 1.0 point from EDSS baseline score (BS) when BS= 5.5 or less, & ≥ 0.5 when BS= above 5.5. Participants with EDSS of 0, progression=change ≥1.5 points. EDSS is based on a standard neurological examination, incorporating 7 functional systems rated & scored as FSSs. EDSS disability scale ranges in 0.5-point steps from 0 (normal)-10 (death). In T25FWT test participants walked 25-foot course as quickly & safely as possible. Score = average of 2 completed trials (in seconds). In 9-HPT, participants had to place & remove pegs 1 by 1 into 9 holes arranged in a board & complete 2 successful trials for each hand & the amount of time (in seconds) required was recorded. In T25FWT & 9-HPT the longer it took to complete test= higher scores, indicating deterioration.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From Baseline in Symbol Digit Modalities Test (SDMT) Score for CASTING Rollover Cohort
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds time. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and minimum of 0. Higher scores indicate improvement.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Time to 8-point Improvement Change in the SDMT Sustained for at Least 48 Weeks From ENSEMBLE Baseline to LIBERTO Week 96
기간: From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

SDMT test consists of a sequence of 110 symbols to be displayed in a maximum 90 seconds and a reference key legend (3 versions are available) with 9 symbols in a given order and their respective matching digits from 1 to 9. This test measures the speed (number of correct paired responses) to pair abstract symbols with specific digits in 90 seconds. Responses were collected orally. The score is the number of correctly paired items in 90 seconds with a maximum score of 110 and a minimum of 0. Higher scores indicate improvement.

From ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Rate of Gadolinium-enhancing Lesions on T1Gd+ Lesions as Detected by Brain MRI
기간: From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of T1 Gd-enhanced lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Rate of New or Enlarging T2 Lesions as Detected by Brain MRI
기간: From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of new and/or enlarging T2 lesions for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From CASTING Week 24 to LIBERTO Week 96 (up to 184 weeks); From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Change in Total T1 Hypointense Lesion Volume Detected by Brain MRI
기간: At LIBERTO Week 96

Estimates are from analysis based on mixed-effect model of repeated measures (MMRM)

At LIBERTO Week 96
Rate of Fluid-Attenuated Inversion Recovery (FLAIR) Late Enhancing Lesions With Leakage as Detected by Brain MRI Over Time
기간: From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)

The rate was calculated by dividing the total number of FLAIR for all participants by the total number of brain MRI scans. The adjusted rate has been reported, for casting cohort adjusted for duration since MS symptom onset (continuous variable), presence of T1 Gd-enhancing lesions at screening (Yes/No), presence of relapses prior to screening as per the CRF (Yes/No), and number of previous DMTs (≤1 vs. >1). For ensemble cohort adjusted by presence or absence of T1 lesions count at ENSEMBLE screening and Baseline EDSS category (<2.5 vs >=2.5).

From LIBERTO Week 24 to LIBERTO Week 96; From ENSEMBLE Week 24 to LIBERTO Week 96 (up to 264 weeks)
Percentage Change in Brain Volume as Detected by Brain MRI Over Time
기간: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in White Matter Volume as Detected by Brain MRI Over Time
기간: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Percentage Change in Cortical Grey Matter Volume as Detected by Brain MRI Over Time
기간: From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)

For CASTING cohort percentage change from normalized brain volume at CASTING Week 8 has been reported and for ENSEMBLE cohort percentage change from normalized brain volume at ENSEMBLE Week 8 has been reported.

From Week 8 of CASTING and ENSEMBLE Cohorts up to LIBERTO Week 96 (CASTING Cohort: up to 3.8 years and ENSEMBLE Cohort: up to 5.8 years)
Time to Treatment Discontinuation
기간: From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
From LIBERTO Baseline to LIBERTO Week 96 (up to 6 years)
Mean Work Productivity and Activity Impairment (WPAI) Score for CASTING Rollover Cohort
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Mean WPAI Score for ENSEMBLE Rollover Cohort
기간: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The WPAI employment status questionnaire is a PRO consisting of 6 items that assess working status, specifically the impact of MS on absenteeism, presentism, work productivity loss and activity impairment over the past 7 days. Four sub scores are calculated and presented as a percentage. Absenteeism = percent work time missed due to problem; Presenteeism = percent impairment while working due to problem; Work productivity= percent overall work impairment due to problem; Activity Impairment = percent activity Impairment due to problem). These sub-scores are transformed to impairment percentages (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in SymptoMScreen Score to LIBERTO Week 96
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in SymptoMScreen Score to LIBERTO Week 96
기간: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The SymptoMScreen comprises 12 distinct domains representing common MS symptoms: mobility, dexterity, vision, fatigue, cognition, bladder function, sensation, dizziness, spasticity, body pain, depression, and anxiety. Limitations associated with each symptom are rated on a 7-point Likert scale ranging from 0 ("not affected at all") to 6 ("total limitation; I am unable to perform most daily activities"). Domain scores are summed to generate a total score ranging from 0 to 72, with higher scores indicating greater symptom-related limitations.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in Multiple Sclerosis Impact Scale (MSIS-29), Physical Scale Score to LIBERTO Week 96
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29 version 2 (MSIS-29v2) is a 29-item patient-reported outcome (PRO) measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better health-related quality of life (HRQoL).

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Physical Scale Score to LIBERTO Week 96
기간: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Physical Scale consists of 20 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw physical impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Change From CASTING Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
기간: CASTING Baseline to LIBERTO Week 96 (up to 4 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

CASTING Baseline to LIBERTO Week 96 (up to 4 years)
Change From ENSEMBLE Baseline in MSIS-29, Psychological Scale Score to LIBERTO Week 96
기간: ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)

The MSIS-29v2 is a 29-item PRO measure designed to assess the physical and psychological impact of MS. The Psychological Scale consists of 9 items, each rated on a 4-point Likert scale ranging from 1 ("Not at all") to 4 ("Extremely"). Item scores are summed to generate a raw impact score, which is then transformed to a 0-100 scale to facilitate interpretation. Lower transformed scores indicate better HRQoL.

ENSEMBLE Baseline to LIBERTO Week 96 (up to 6 years)
Number of Participants With Adverse Events (AEs)
기간: From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

From CASTING Baseline to LIBERTO SFU (up to 4.9 years); From ENSEMBLE Baseline to LIBERTO SFU (up to 6.9 years)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Clinical Trials, Hoffmann-La Roche

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 7월 12일

기본 완료 (실제)

2025년 7월 17일

연구 완료 (실제)

2025년 7월 17일

연구 등록 날짜

최초 제출

2018년 6월 25일

QC 기준을 충족하는 최초 제출

2018년 7월 23일

처음 게시됨 (실제)

2018년 7월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 28일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • MN39158
  • 2017 (미국 NIH 보조금/계약)
  • 2017-004886-29 (EudraCT 번호)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다